{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:56:45Z","timestamp":1789617405468,"version":"build-2803163510"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1156426"],"award-info":[{"award-number":["1156426"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To utilize the Antifungal National Antimicrobial Prescribing Survey (Antifungal NAPS), a novel tool utilizing international consensus metrics for antifungal stewardship, to assess the quality of systemic antifungal prescribing in Australian hospitals, in order to identify quality improvement targets.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Participating hospitals were directed to audit all systemic antifungals or focus on a specific antifungal drug or class. Data entry into the Antifungal NAPS online portal occurred between October 2022 and June 2023. The data collection tool comprised patient details, reasons precluding use of antifungals, prescription details (guideline compliance, appropriateness, and reasons for inappropriate prescribing) and patient outcomes. Descriptive statistics were used to analyse the data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eleven hospitals contributed data for 516 prescriptions for 438 patients. Of these, 77.1% of prescriptions were appropriate, with the highest appropriateness for prophylactic (189\/222; 85.1%), followed by directed (105\/130; 80.8%) and empirical therapy (104\/164; 63.4%). Fluconazole was the most commonly prescribed agent, which had the lowest rate of appropriateness (132\/209; 63.2%). The most common reasons for inappropriate prescribing were no antifungal required (35\/105; 33.3%), incorrect dose or frequency (30\/105; 28.6%) and incorrect duration (19\/105; 18.1%). Compliance with guidelines was 73.6%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study outlines the successful implementation of the Antifungal NAPS, a standardized electronic audit tool for the assessment of antifungal prescribing quality. Key areas for quality improvement identified were the overuse of empirical fluconazole for urinary tract and intra-abdominal infections, the importance of invasive fungal infection risk assessment to guide prophylaxis prescribing and greater infectious diseases and antifungal stewardship oversight of antifungal prescribing to guide optimal prescribing.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf044","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T04:15:09Z","timestamp":1738556109000},"page":"1127-1136","source":"Crossref","is-referenced-by-count":2,"title":["Assessing the appropriateness of antifungal prescribing: key results from the implementation of a novel audit tool in Australian hospitals"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2988-1676","authenticated-orcid":false,"given":"A","family":"Khanina","sequence":"first","affiliation":[{"name":"The National Centre for Infections in Cancer, Peter MacCallum Cancer Centre , 305 Grattan St, Melbourne, Victoria 3000 ,","place":["Australia"]},{"name":"Department of Infectious Diseases, Peter MacCallum Cancer Centre , 305 Grattan St, Melbourne, Victoria 3000 ,","place":["Australia"]},{"name":"Sir Peter MacCallum Department of Oncology, The University of Melbourne , Melbourne, Victoria 3010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5264-2447","authenticated-orcid":false,"given":"N","family":"Singh","sequence":"additional","affiliation":[{"name":"The National Centre for Infections in Cancer, Peter MacCallum Cancer Centre , 305 Grattan St, Melbourne, Victoria 3000 ,","place":["Australia"]},{"name":"Department of Infectious Diseases, Peter MacCallum Cancer Centre , 305 Grattan St, Melbourne, Victoria 3000 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"James","sequence":"additional","affiliation":[{"name":"The National Centre for Antimicrobial Stewardship, Department of Infectious Diseases, University of Melbourne, The Peter Doherty Institute for Infection and Immunity , 792 Elizabeth St, Melbourne, Victoria 3000 ,","place":["Australia"]},{"name":"The Royal Melbourne Hospital Guidance Group, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity , 792 Elizabeth St, Melbourne, Victoria 3000 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5022-9060","authenticated-orcid":false,"given":"D C M","family":"Kong","sequence":"additional","affiliation":[{"name":"The National Centre for Antimicrobial Stewardship, Department of Infectious Diseases, University of Melbourne, The Peter Doherty Institute for Infection and Immunity , 792 Elizabeth St, Melbourne, Victoria 3000 ,","place":["Australia"]},{"name":"Centre for Medicine Use and Safety, Monash Institute of Pharmaceutical Sciences, Monash University , 381 Royal Parade, Parkville, Victoria 3010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-314X","authenticated-orcid":false,"given":"M A","family":"Slavin","sequence":"additional","affiliation":[{"name":"The National Centre for Infections in Cancer, Peter MacCallum Cancer Centre , 305 Grattan St, Melbourne, Victoria 3000 ,","place":["Australia"]},{"name":"Department of Infectious Diseases, Peter MacCallum Cancer Centre , 305 Grattan St, Melbourne, Victoria 3000 ,","place":["Australia"]},{"name":"Sir Peter MacCallum Department of Oncology, The University of Melbourne , Melbourne, Victoria 3010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K A","family":"Thursky","sequence":"additional","affiliation":[{"name":"The National Centre for Infections in Cancer, Peter MacCallum Cancer Centre , 305 Grattan St, Melbourne, Victoria 3000 ,","place":["Australia"]},{"name":"Department of Infectious Diseases, Peter MacCallum Cancer Centre , 305 Grattan St, Melbourne, Victoria 3000 ,","place":["Australia"]},{"name":"Sir Peter MacCallum Department of Oncology, The University of Melbourne , Melbourne, Victoria 3010 ,","place":["Australia"]},{"name":"The National Centre for Antimicrobial Stewardship, Department of Infectious Diseases, University of Melbourne, The Peter Doherty Institute for Infection and Immunity , 792 Elizabeth St, Melbourne, Victoria 3000 ,","place":["Australia"]},{"name":"The Royal Melbourne Hospital Guidance Group, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity , 792 Elizabeth St, Melbourne, Victoria 3000 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"2025040208384168500_dkaf044-B1","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.bbmt.2014.03.004","article-title":"Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"20","author":"Girmenia","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025040208384168500_dkaf044-B2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.diagmicrobio.2012.10.001","article-title":"Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy","volume":"75","author":"Neofytos","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2025040208384168500_dkaf044-B3","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2025040208384168500_dkaf044-B4","doi-asserted-by":"publisher","first-page":"ofad059","DOI":"10.1093\/ofid\/ofad059","article-title":"Invasive Scedosporium and Lomentospora prolificans infections in Australia: a multicenter retrospective cohort study","volume":"10","author":"Neoh","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025040208384168500_dkaf044-B5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/jac\/dkad345","article-title":"Costs associated with invasive Scedosporium and Lomentospora prolificans infections: a case-control study","volume":"79","author":"Neoh","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2025040208384168500_dkaf044-B6","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1128\/AAC.01423-10","article-title":"Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach","volume":"55","author":"Ananda-Rajah","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208384168500_dkaf044-B7","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025040208384168500_dkaf044-B8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/jof5030067","article-title":"Emerging fungal infections: new patients, new patterns, and new pathogens","volume":"5","author":"Friedman","year":"2019","journal-title":"J Fungi (Basel)"},{"key":"2025040208384168500_dkaf044-B9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/QCO.0b013e32834e0680","article-title":"The case for antifungal stewardship","volume":"25","author":"Ananda-Rajah","year":"2012","journal-title":"Curr Opin Infect Dis"},{"issue":"Suppl 1","key":"2025040208384168500_dkaf044-B10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/imj.15586","article-title":"Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021","volume":"51","author":"Khanina","year":"2021","journal-title":"Intern Med J"},{"issue":"Suppl 3","key":"2025040208384168500_dkaf044-B11","doi-asserted-by":"publisher","first-page":"S175","DOI":"10.1093\/infdis\/jiaa394","article-title":"Core recommendations for antifungal stewardship: a statement of the Mycoses Study Group Education and Research Consortium","volume":"222","author":"Johnson","year":"2020","journal-title":"J Infect Dis"},{"key":"2025040208384168500_dkaf044-B12","author":"Australian Commission on Safety and Quality in Health Care"},{"key":"2025040208384168500_dkaf044-B13","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1093\/jac\/dkv047","article-title":"Measuring antimicrobial prescribing quality in Australian hospitals: development and evaluation of a national antimicrobial prescribing survey tool","volume":"70","author":"James","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2025040208384168500_dkaf044-B14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/tropicalmed9010008","article-title":"The impact of antifungal stewardship on clinical and performance measures: a global systematic review","volume":"9","author":"Albahar","year":"2023","journal-title":"Trop Med Infect Dis"},{"key":"2025040208384168500_dkaf044-B15","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025040208384168500_dkaf044-B16","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/myc.12960","article-title":"Defining breakthrough invasive fungal infection\u2013position paper of the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology","volume":"62","author":"Cornely","year":"2019","journal-title":"Mycoses"},{"key":"2025040208384168500_dkaf044-B17","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2025040208384168500_dkaf044-B18","author":"Australian Bureau of Statistics"},{"key":"2025040208384168500_dkaf044-B19","author":"Australian Institute of Health and Welfare"},{"issue":"Suppl 7","key":"2025040208384168500_dkaf044-B20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/imj.15588","article-title":"Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021","volume":"51","author":"Teh","year":"2021","journal-title":"Intern Med J"},{"issue":"Suppl 7","key":"2025040208384168500_dkaf044-B21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/imj.15587","article-title":"Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021","volume":"51","author":"Chau","year":"2021","journal-title":"Intern Med J"},{"issue":"Suppl 7","key":"2025040208384168500_dkaf044-B22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/imj.15589","article-title":"Consensus guidelines for the diagnosis and management of invasive candidiasis in haematology, oncology and intensive care settings, 2021","volume":"51","author":"Keighley","year":"2021","journal-title":"Intern Med J"},{"issue":"Suppl 7","key":"2025040208384168500_dkaf044-B23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/imj.15590","article-title":"Consensus guidelines for the diagnosis and management of cryptococcosis and rare yeast infections in the haematology\/oncology setting, 2021","volume":"51","author":"Chang","year":"2021","journal-title":"Intern Med J"},{"issue":"Suppl 7","key":"2025040208384168500_dkaf044-B24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/imj.15591","article-title":"Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021","volume":"51","author":"Douglas","year":"2021","journal-title":"Intern Med J"},{"issue":"Suppl 7","key":"2025040208384168500_dkaf044-B25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/imj.15592","article-title":"Consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than Aspergillus in the haematology\/oncology setting, 2021","volume":"51","author":"Bupha-Intr","year":"2021","journal-title":"Intern Med J"},{"key":"2025040208384168500_dkaf044-B26","doi-asserted-by":"publisher","first-page":"e13623","DOI":"10.1111\/ctr.13623","article-title":"Candida infections in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Aslam","year":"2019","journal-title":"Clin Transplant"},{"key":"2025040208384168500_dkaf044-B27","doi-asserted-by":"publisher","first-page":"e13544","DOI":"10.1111\/ctr.13544","article-title":"Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Husain","year":"2019","journal-title":"Clin Transplant"},{"key":"2025040208384168500_dkaf044-B28","author":"Therapeutic Guidelines"},{"key":"2025040208384168500_dkaf044-B29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/jac\/dkaa409","article-title":"Establishing essential metrics for antifungal stewardship in hospitals: the results of an international Delphi survey","volume":"76","author":"Khanina","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2025040208384168500_dkaf044-B30","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/jac\/dkad085","article-title":"Validation of the Antifungal National Antimicrobial Prescribing Survey (AF-NAPS) quality assessment tool","volume":"78","author":"Khanina","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025040208384168500_dkaf044-B31","author":"Australian Commission on Safety and Quality in Health Care"},{"key":"2025040208384168500_dkaf044-B32","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1093\/jac\/dkx047","article-title":"Changing epidemiology of candidaemia in Australia","volume":"72","author":"Chapman","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025040208384168500_dkaf044-B33","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3389\/fmicb.2016.00915","article-title":"A prospective surveillance study of candidaemia: epidemiology, risk factors, antifungal treatment and outcome in hospitalized patients","volume":"7","author":"Rajendran","year":"2016","journal-title":"Front Microbiol"},{"key":"2025040208384168500_dkaf044-B34","author":"Therapeutic Guidelines"},{"key":"2025040208384168500_dkaf044-B35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1128\/CMR.00066-16","article-title":"Antimicrobial stewardship: how the microbiology laboratory can right the ship","volume":"30","author":"Morency-Potvin","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"2025040208384168500_dkaf044-B36","author":"Therapeutic Guidelines"},{"key":"2025040208384168500_dkaf044-B37","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1007\/s11096-016-0382-6","article-title":"Drug utilization study of systemic antifungal agents in a Brazilian tertiary care hospital","volume":"38","author":"de Souza","year":"2016","journal-title":"Int J Clin Pharm"},{"key":"2025040208384168500_dkaf044-B38","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1086\/587633","article-title":"Inappropriate use of antifungal medications in a tertiary care center in Thailand: a prospective study","volume":"29","author":"Sutepvarnon","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2025040208384168500_dkaf044-B39","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/myc.13514","article-title":"Antifungal prescription practices and consumption in a tertiary care hospital of a developing country","volume":"65","author":"Kaur","year":"2022","journal-title":"Mycoses"},{"key":"2025040208384168500_dkaf044-B40","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1093\/jac\/dks256","article-title":"Adherence to recommendations for the use of antifungal agents in a tertiary care hospital","volume":"67","author":"Nivoix","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2025040208384168500_dkaf044-B41","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1080\/10428194.2019.1590570","article-title":"Auditing fungal disease in leukemia patients in a tertiary care center: opportunities and challenges for an antifungal stewardship program","volume":"60","author":"Paige","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"2025040208384168500_dkaf044-B42","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s10096-018-3335-2","article-title":"Repeated antifungal use audits are essential for selecting the targets for intervention in antifungal stewardship","volume":"37","author":"Valerio","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025040208384168500_dkaf044-B43","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1093\/jac\/dku053","article-title":"Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed","volume":"69","author":"Valerio","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2025040208384168500_dkaf044-B44","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1093\/cid\/ciy849","article-title":"Impact of infectious disease consultation on clinical management and mortality in patients with candidemia","volume":"68","author":"Lee","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025040208384168500_dkaf044-B45","doi-asserted-by":"publisher","first-page":"e0215996","DOI":"10.1371\/journal.pone.0215996","article-title":"The impact of infectious disease consultation in candidemia in a tertiary care hospital in Japan over 12\u2005years","volume":"14","author":"Ishikane","year":"2019","journal-title":"PLoS One"},{"key":"2025040208384168500_dkaf044-B46","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1080\/1120009X.2018.1507086","article-title":"Impact of infectious diseases consultation as a part of an antifungal stewardship programme on candidemia outcome in an Italian tertiary-care, university hospital","volume":"30","author":"Menichetti","year":"2018","journal-title":"J Chemother"},{"key":"2025040208384168500_dkaf044-B47","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/cid\/ciw786","article-title":"Impact of infectious diseases consultation on mortality of cryptococcal infection in patients without HIV","volume":"64","author":"Spec","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025040208384168500_dkaf044-B48","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1093\/jac\/dkae226","article-title":"Cultivating global antimicrobial stewardship: linguistic and cultural validation of the Australian National Antimicrobial Prescribing Survey appropriateness assessment definitions for Portugal","volume":"79","author":"Palos","year":"2024","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/4\/1127\/61865954\/dkaf044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/4\/1127\/61865954\/dkaf044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T09:25:14Z","timestamp":1743585914000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/4\/1127\/8010939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2,13]]},"published-print":{"date-parts":[[2025,4,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf044","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,2,13]]}}}